EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations

Martin Regensburger, Chi Wang Ip, Zacharias Kohl, Christoph Schrader, Peter P Urban, Jan Kassubek, Wolfgang H Jost

Journal of Neural Transmission · 2023-06 · 130 (6) · 847-861

DOI: 10.1007/s00702-023-02623-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 24.03.2023. Verfasst von Martin Regensburger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. martin.regensburger@uk-erlangen.de. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Friedrich-Alexander-Universität Erlangen-Nürnberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are major strategies to reduce levodopa degradation and thus to increase and prolong its effect in striatal dopaminergic neurotransmission in Parkinson’s disease patients. While selegiline/rasagiline and tolcapone/entacapone have been available on the market for more than one decade, safinamide and opicapone have been approved in 2015 and 2016, respectively. Meanwhile, comprehensive data from several post-authorization studies have described the use and specific characteristics of the individual substances in clinical practice under real-life conditions. Here, we summarize current knowledge on both medication classes, with a focus on the added clinical value in Parkinson’s disease. Furthermore, we outline practical considerations in the treatment of motor fluctuations and provide an outlook on ongoing studies with MAO-B and COMT inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansAntiparkinson AgentsMonoamine OxidaseCatechol O-MethyltransferaseLevodopaCatechol O-Methyltransferase InhibitorsMonoamine Oxidase Inhibitors

Stichwörter der Autor:innen

COMT inhibitorsMAO-B inhibitorsMotor fluctuationsParkinson’s disease

Substanzen

Antiparkinson AgentsMonoamine OxidaseCatechol O-MethyltransferaseLevodopaCatechol O-Methyltransferase InhibitorsMonoamine Oxidase InhibitorsCOMT protein, human

Autor:innen und Institutionen

  • Department of Molecular Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. martin.regensburger@uk-erlangen.de.
  • Department of Neurology, University Hospital of Würzburg, Würzburg, Germany.
  • Department of Neurology, University of Regensburg, Regensburg, Germany.
  • Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Abt. für Neurologie, Asklepios Klinik Barmbek, Hamburg, Germany.
  • Department of Neurology, University Hospital Ulm, Ulm, Germany.

Förderung

  • Friedrich-Alexander-Universität Erlangen-Nürnberg

Zitieren

APA

Regensburger, M., Ip, C. W., Kohl, Z., Schrader, C., Urban, P. P., Kassubek, J., & Jost, W. H. (2023). Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations. Journal of Neural Transmission, 130(6), 847-861. https://doi.org/10.1007/s00702-023-02623-8

Vancouver

Regensburger M, Ip CW, Kohl Z, Schrader C, Urban PP, Kassubek J, et al. Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations. Journal of Neural Transmission. 2023;130(6):847-861. doi:10.1007/s00702-023-02623-8

BibTeX
@article{Regensburger2023,
  author = {Regensburger, Martin and Ip, Chi Wang and Kohl, Zacharias and Schrader, Christoph and Urban, Peter P and Kassubek, Jan and Jost, Wolfgang H},
  title = {Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations},
  journal = {Journal of Neural Transmission},
  year = {2023},
  volume = {130},
  number = {6},
  pages = {847--861},
  doi = {10.1007/s00702-023-02623-8}
}
Kostenlos starten →